BVNKF OTC
Bavarian Nordic A/S
1W: +3.4%
1M: +3.4%
3M: +21.6%
YTD: +14.1%
1Y: -7.3%
3Y: +13.2%
5Y: -28.2%
$33.66
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$2.6B
52W Range27.56-37.22
Volume3
Avg Volume109
Beta0.94
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOPaul John Chaplin
Employees1,795
SectorHealthcare
IndustryBiotechnology
IPO Date2010-10-15
Websitebavarian-nordic.com
Philip Heymans Alle 3
Hellerup, CR 2900
DK
Hellerup, CR 2900
DK
45 33 26 83 83
About Bavarian Nordic A/S
Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.
Latest News
Bavarian Nordic AS (BVNKF) (Q2 2026) Earnings Call Highlights: Strong H1 Growth and Upgraded ...
Bavarian Nordic A/S 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:BVNRY) 2026-08-21 - Seeking Alpha
BVNKF Looks 13.6% Overvalued on GF Value™ - GuruFocus
Bavarian Nordic AS (BVNKF) (Q2 2026) Earnings Call Highlights: Strong H1 Growth and Upgraded ... By GuruFocus - Investing.com Canada
Bavarian Nordic A/S reports Q2 results; upgrades FY 2026 outlook
Recent Insider Trades
No insider trades found